Homocysteine and arterial thrombosis: Challenge and opportunity
- 1 January 2010
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 103 (05), 942-961
- https://doi.org/10.1160/th09-06-0393
Abstract
The correlation between homocysteine and vascular disease has been assessed in several clinical studies that demonstrated that elevation of plasma total homocysteine (tHcy) was an independent risk factor for atheriosclerotic disease. Major advances of homocysteine metabolism disorders have been made during the last few years, encompassing the rare homozygous enzyme deficiencies, as well as more common milder abnormalities. In experimental and clinical studies, a homocysteine-mediated oxidant stress has been shown to trigger platelet activation, in turn leading to a tendency to thrombosis, in patients with severe hyperhomocysteinaemia. Likewise, the hypomethylation hypothesis on acquired hyperhomocysteinaemia (chronic renal disease) and the interrelationship between hyperhomocysteinaemia and impaired fibrinolysis, have added further biological plausibility to the role for hyperhomocysteinaemia in vascular medicine. However, whether hyperhomocysteinaemia is causal or a marker of vascular disease, and whether plasma tHcy is only an indicator of the metabolic status remains to be clarified. The role of the intake of some vitamins (folic acid, vit.B12, vit.B6) on cardiovascular disease (CVD) is poorly understood: in spite of the lowering of homocysteine (Hcy) levels, vitamin supplementation failed to exert significant effects on cardiovascular risk. On the other hand, although some lipid-modifying treatments increase Hcy levels in diabetics, there is no evidence that this attenuates the beneficial effects of such treatments on the cardiovascular risk. Because of these uncertainties in the area, the data available do not provide support for routine screening and treatment for elevated Hcy to prevent CVD.This publication has 60 references indexed in Scilit:
- Comparison of the effect of different homocysteine concentrations on clot formation using human plasma and purified fibrinogenThrombosis and Haemostasis, 2008
- Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease: Not ValidatedJournal of the American College of Cardiology, 2006
- Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trialsAmerican Heart Journal, 2006
- Folate therapy and in-stent stenosis after coronary stentingJournal of Vascular Surgery, 2004
- Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitusThe American Journal of Cardiology, 2004
- Enhancement by Homocysteine of Plasminogen Activator Inhibitor-1 Gene Expression and Secretion from Vascular Endothelial and Smooth Muscle CellsBiochemical and Biophysical Research Communications, 2000
- HOMOCYSTEINE METABOLISMAnnual Review of Nutrition, 1999
- Hyperhomocysteinemia and Hypofibrinolysis in Young Adults With Ischemic StrokeStroke, 1999
- A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians.Journal of the American College of Nutrition, 1996
- A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.Stroke, 1994